Category: News

Gastrointestinal stromal tumour (GIST) is a rare cancer that presents in various forms and can affect individuals of all ages. The prognosis for metastatic GIST is poor. All current targeted therapies rely on tyrosine kinase inhibitors, which control disease progression for a limited time before patients exhaust available treatment options. Moreover, pediatric, adolescent, wild-type, and […]

Sarcomas are rare, difficult-to-diagnose, and hard-to-treat cancers that can affect people of any age, accounting for up to 20% of all adolescent cancers. These cancers originate from different tissue types, resulting in many subtypes, such as gastrointestinal stromal tumors (GIST), liposarcomas, and leiomyosarcomas. They often grow undetected until they reach an advanced stage. This highlights […]

Meet our CEO Mikael Maksimow  in the LSX World Congress in London on 29-30 April 2024!

We are excited to attend the ESMO Sarcoma and rare cancers Congress next week in Lugano. We are looking forward to learn the latest scientific advancements, connect with KOLs, engage with patient advocacy groups and network within the industry. Do not hesitate to reach out to our CEO, Mikael Maksimow, if you would like to […]

International rare disease day! Over 300 million people around the world are living with a rare disease! Then imagine how many of us are affected by rare diseases – whether as patients ourselves, caregivers, family members, or friends. While individually these conditions may affect only a small number of people, collectively they represent a significant portion […]

More great news before Christmas! We are happy to announce the appointment of Dr. Maria Lahtinen as the Chief Development Officer. Dr. Lahtinen has diligently served as the company’s Quality Director for the past year. The company’s CEO, Dr. Maksimow, expressed his excitement, stating, “I am thrilled to have Maria as our CDO, especially as we progress SAR003, […]

The board of Sartar Therapeutics Oy is delighted to announce Dr. Mikael Maksimow as the new CEO of the company. Dr. Maksimow officially assumed his role on December 7th, following more than two years of dedicated service as Sartar’s Chief Operating Officer. “We are excited to have Mikael, a seasoned, dynamic, and innovative CEO, spearheading […]

Sartar Therapeutics is present in Nordic Life Science Days! Come and meet us or book a meeting during the event! We are looking for Series A funding or co-development partners for our SAR003 treatment for GISt and other soft tissue sarcoma subtypes.

CTOS meeting in Dublin was well organised with highly interesting program. It was great to meet old friends and make new ones. We had very good talks with key opinion leaders, investors and patient advocacy groups. 

We are delighted to announce that Sartar Therapeutics received Orphan Drug Designation for GIST from the U.S. Food & Drug administration (FDA). This is a great addition to our Orphan Drug Designation in EU granted by the European Medicines Agency (EMA) earlier this year. See Orphan Drug Designation in FDA’s database.